Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction

Harari, Rafael; Baber, Usman

doi:10.1016/j.iccl.2016.06.007

Cited by 2 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…STEMI typically occurs due to plaque rupture or endothelial erosion, leading to thrombus formation within the artery and subsequently impedes blood flow [52] . High-quality pharmacologic treatment is essential for STEMI patients while en route to a PCI center and during PCI.…”

Section: Current and Emergent Antithrombotic Therapy In Stemimentioning

confidence: 99%

“…Antithrombotic therapy, including anticoagulant and antiplatelet agents, are critically important. The ideal choice of pharmacologic treatment should weigh benefits and risks to the patient and take into account comorbid conditions [52] , [53] ( Fig. 3 ).…”

Section: Current and Emergent Antithrombotic Therapy In Stemimentioning

confidence: 99%

“…Aspirin is an irreversible cyclooxygenase receptor inhibitor-1 and prevents platelet activation and aggregation [52] . Low-dose aspirin (81 mg) was shown to be equally effective with less bleeding risk than high-dose (325 mg) and has been incorporated into the guidelines for secondary prevention of cardiovascular events after STEMI [15] , [31] .…”

Section: Current and Emergent Antithrombotic Therapy In Stemimentioning

confidence: 99%

See 2 more Smart Citations

STEMI care 2021: Addressing the knowledge gaps

Yıldız

Wade

Henry

2021

American Heart Journal Plus: Cardiology Research and Practice

View full text Add to dashboard Cite

Tremendous progress has been made in the treatment of ST-segment elevation myocardial infarction (STEMI), the most severe and time-sensitive acute coronary syndrome. Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion, which has stimulated the development of regional STEMI systems of care with standardized protocols designed to optimize care. However, challenges remain for patients with cardiogenic shock, out-of-hospital cardiac arrest, an expected delay to reperfusion (>120 min), in-hospital STEMI, and more recently, those with Covid-19 infection. Ultimately, the goal is to provide timely reperfusion with primary PCI coupled with the optimal antiplatelet and anticoagulant therapies. We review the challenges and provide insights into the remaining knowledge gaps for contemporary STEMI care.

show abstract

Section: Current and Emergent Antithrombotic Therapy In Stemimentioning

confidence: 99%

Section: Current and Emergent Antithrombotic Therapy In Stemimentioning

confidence: 99%